©2006, ICHE 12 Weeks of Vildagliptin Therapy vs Placebo in Patients Taking Metformin Purpose –To assess efficacy of vildagliptin in patients with T2DM taking metformin Trial design –12-week, randomized, double-blind, placebo- controlled trial, with a 40-week extension –Patients continuing metformin treatment –Random assignments to addition of placebo or vildagliptin Primary end points: A1C and FPG after 12 and 52 weeks of therapy Ahrén.
{}